Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $20.51 USD
Change Today +0.395 / 1.96%
Volume 355.4K
DVAX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

dynavax technologies corp (DVAX) Snapshot

Open
$19.99
Previous Close
$20.11
Day High
$21.03
Day Low
$19.92
52 Week High
03/24/15 - $26.89
52 Week Low
05/8/14 - $12.50
Market Cap
593.3M
Average Volume 10 Days
335.0K
EPS TTM
$-3.35
Shares Outstanding
28.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DYNAVAX TECHNOLOGIES CORP (DVAX)

dynavax technologies corp (DVAX) Related Businessweek News

No Related Businessweek News Found

dynavax technologies corp (DVAX) Details

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. It development programs focus on the areas of vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The company’s product pipeline includes HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; SD-101, a CpG TLR9 agonist for the treatment of cancer immunotherapy that is in Phase I/II clinical trials; AZD1419, a drug candidate for the treatment of asthma, which has completed Phase I trial; DV1179, a TLR7/9 inhibitor that is in Phase I clinical trial for autoimmune or inflammatory conditions; and DV230-Nanoparticle, a second generation adjuvant that is in preclinical studies. It has a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease; and strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

197 Employees
Last Reported Date: 03/5/15
Founded in 1996

dynavax technologies corp (DVAX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $515.0K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $354.2K
Senior Vice President of Operations and Quali...
Total Annual Compensation: $309.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $440.0K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $358.8K
Compensation as of Fiscal Year 2014.

dynavax technologies corp (DVAX) Key Developments

Dynavax Technologies Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Dynavax Technologies Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $2,277,000 against $2,847,000 for the same period in the last year. Loss from operations was $22,413,000 against $12,992,000 for the same period in the last year. Net loss was $22,286,000 against $13,056,000 for the same period in the last year. Net loss allocable to common stockholders was $22,286,000 or $0.85 per basic and diluted share against $21,525,000 or $0.91 per basic and diluted share for the same period in the last year. For the year, the company reported total revenues of $11,032,000 against $11,251,000 for the same period in the last year. Loss from operations was $91,311,000 against $66,488,000 for the same period in the last year. Net loss was $90,722,000 against $66,720,000 for the same period in the last year. Net loss allocable to common stockholders was $90,722,000 or $3.45 per basic and diluted share against $75,189,000 or $3.83 per basic and diluted share for the same period in the last year.

Dynavax Technologies Corporation Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 09:30 AM

Dynavax Technologies Corporation Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 09:30 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Eddie Gray, Chief Executive Officer and Director.

Dynavax Technologies Corporation Announces Board Changes

Dynavax Technologies Corporation announced the appointment of Laura Brege to its Board of Directors and Audit Committee. Denise Gilbert, a director and the Chair of the Audit Committee since 2004, will retire from her positions with the company following the next Audit Committee meeting, whereupon Ms. Brege will become Chair of the Committee. Ms. Brege is President and Chief Executive Officer of Nodality Inc. She has over 20 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. Prior to joining Nodality in 2012, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals Inc., including Executive Vice President and Chief Operating OfficerPrior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management. Previously, Ms. Brege was SVP and Chief Financial Officer at COR Therapeutics.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVAX:US $20.51 USD +0.395

DVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $17.07 USD +0.26
Argos Therapeutics Inc $7.57 USD -0.42
GenVec Inc $2.42 USD -0.10
Inovio Pharmaceuticals Inc $8.42 USD +0.26
Vical Inc $0.92 USD -0.03
View Industry Companies
 

Industry Analysis

DVAX

Industry Average

Valuation DVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.9x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYNAVAX TECHNOLOGIES CORP, please visit www.dynavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.